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Background: This study investigates test-retest and inter-item consistency of Alcohol Drog Diagnos InStrument
(ADDIS), a structured interview to diagnose substance use disorders according to ICD-10, DSM-IV and DSM-5. ADDIS,
the Swedish version of SUDDS, is the only instrument in Swedish that produces diagnostic proposals specific to all
drug categories, and for all three diagnostic systems. Screening of stressful life events, anxiety, and depression is also
included.
Methods: Thirty patients at addiction treatment facilities were interviewed for diagnostic assessment and re-interviewed
after one week.
Results: ADDIS has excellent internal consistency. There is also very high test-retest correlation on number of fulfilled
criteria for all diagnostic systems. Agreement of diagnostic proposals is substantial, mean absolute agreement is
excellent, and mean systematic correlation is almost perfect.
Conclusion: ADDIS is a reliable tool for specific diagnostic assessment of SUDs.
Keywords: Alcohol and drug dependence, Diagnoses, Assessment, Global reliability, Internal consistencyIn Sweden, substance use disorders (SUDs) are diagnosed
according to ICD-10 [1]. In research, and internationally,
they may also be diagnosed according to DSM-IV [2] or
the new DSM-5 [3]. As of today (2015), there are three in-
struments for diagnostic assessment of SUDs with man-
uals translated into Swedish: SCID-I (Structured Clinical
Interview for the DSM-IV [axis I disorders]) [4], MINI
(The Mini-International Neuropsychiatric Interview) [5,6]
and ADDIS [7]. Of these three, ADDIS is the only one that
provides detailed information on all substances as well as
the only one that produces diagnostic proposals for all
three diagnostic systems. With such ambitions, there
should be high quality demands.
ADDIS (Alcohol Drog Diagnos InStrument) is the
Swedish version of SUDDS (Substance Use Disorder
Diagnostic Schedule) [8], a tool to diagnose SUDs. SUDDS
was constructed as an improvement for NIMH-DIS (The
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article, unless otherwise stated.Schedule-Version II), a structured interview for the assess-
ment of psychiatric disorders with high validity and
reliability [9]. SUDDS is an event-oriented structured
diagnostic interview that yields information for lifetime
and current diagnosis (the past 12 months) of alcohol and
other drug dependencies and abuse according to DSM.
The latest version is SUDDS-5 [10].
ADDIS was translated and introduced to Sweden, with
cultural adaptions, in 1987 by Wickström, who was also
responsible for revising ADDIS making it compatible
with DSM-III-R, DSM-IV and ICD-10. ADDIS consists
of 75 questions, of which 47 are specific, behaviourally
oriented questions on alcohol and other drugs based on
DSM’s and ICD’s criteria for abuse/harmful use and de-
pendence. Replies on specific questions are transferred
to checklists for the diagnostic system used, i.e. ICD-10,
DSM-IV or DSM-5, with columns for each drug category,
resulting in specified current and lifetime diagnostic pro-
posals. In addition, ADDIS includes smaller sections of
screening for stressful experiences and problems concern-
ing depression and anxiety.ed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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when assessed for inpatient alcohol and drug addiction
treatment, was presented by Davis et al. [11]. SUDDS
has good agreement with diagnostic assessment of expe-
rienced clinicians (Ƙ = .71 - .87). Test-retests show high
correlation (R = .81 - .90), indicating high global consist-
ence. When diagnoses based on SUDDS were compared
to assessments by clinicians, the false negatives were less
than one per cent and none were false positive [12].
Dependence and abuse appear as distinctive categories
and reliability is similar in various ethnic groups
(Afro-Americans, Hispanics, Native Americans and
Caucasians), with internal consistency (α) for depend-
ence varying between .93 and .97, and for abuse be-
tween .84 and .90 [13].
The Swedish ADDIS shows good construct validity
concerning alcohol in two populations: a clinical popula-
tion and a DWI population [14]. Principal Component
Analysis found the two DSM-IV constructs – depend-
ence and abuse – to be homogeneous with all items hav-
ing factor loadings above .40 and acceptable explained
variances. Separate analyses for the two populations and
for women provided similar results. Discriminant validity
was assessed by means of Discriminant Analysis. ADDIS
could correctly classify 93.8 per cent of the two samples.
Cronbach’s alpha is either satisfying or excellent in all
analyses – both on criterion level and on item level, and
for the different groups (clinical, DWI, women).
Sensitivity and specificity of ADDIS concerning alco-
hol and drug use disorders in comparison to the SCID
and in comparison with a LEAD golden standard
(Longitudinal, Expert, All Data) was studied by Gerdner
et al. [15]. There is satisfactory agreement between
ADDIS and SCID, although ADDIS is more sensitive
than SCID. ADDIS demonstrates substantial to perfect
agreement with the LEAD golden standard concerning
alcohol as well as drugs, both lifetime and last year, and
shows excellent to perfect overall sensitivity and specifi-
city. Severity ratings (number of criteria) are almost per-
fectly in agreement with the LEAD standard.
Although internal consistency of ADDIS was pre-
sented concerning alcohol and DSM-IV, there is no pre-
vious study on the reliability of ADDIS concerning all
drug categories and all three diagnostic systems. This
present study is designed to measure the reliability of
ADDIS, both as global consistency and as internal
consistency, concerning the various drug categories. In-
ternal consistency, or inter-item consistency, concerns
how well various items of a test correlate with each
other, while global consistency concerns how well the
total test agrees with itself, if used at different occasions
under same or similar circumstances. Global consistency
can be studied either as inter-rater reliability, i.e. how well
different raters agree with each other using the sameinstrument, or as test-retest reliability, i.e. the ability of a
test to produce the same measure at different occasions
under similar conditions. Test-retest is therefore the re-
peatability of a test, and is explored in repeating the test
on the same individuals. Test-retest is sometimes found to
be more critical, showing lower agreement, than inter-
rater reliability in psychiatric assessment [16,17].
Test-retest reliability is desired for constructs that are
not expected to change within a short time. Behaviours,
e.g. drinking or using drugs, may differ from one day to
another. An alcohol dependent person may one day be
“on the wagon” and another day, after a relapse, be in-
volved in binge drinking. Diagnoses, however, are sup-
posed to be relatively stable. Instruments used for
diagnostic assessment should therefore produce the same
diagnostic proposal for the same person when assessed on
a new occasion shortly after. These diagnoses should be
repeatable within a time-span suitable for the condition
assessed. Persons may recover, so that they no longer meet
the criteria. SUDs diagnoses according to ICD-10 and
DSM-IV are assessed as current diagnosis of dependence,
substance abuse or harmful use, and in DSM-5 as
substance use disorder if the person has met the criteria
during the past 12 months. Test-retest should have a
time-span between tests long enough for the test person
not to remember previous replies when retested, but not
so long that real change is likely to have occurred.
The aim here is to explore the reliability of ADDIS, as
test-retest as well as inter-item consistency for the cri-
teria and diagnostic proposals on SUDs according to
ICD-10, DSM-IV and DSM-5, specific to various drug
categories, and for its three screening tests concerning
stress, anxiety and depression.
Methods
The study was done as a quality assurance study in co-
operation with alcohol and drug treatment facilities,
where patients agreed to participate in a test-retest in-
vestigation of ADDIS. Trained interviewers among the
treatment staff carried out the interviews. In this study,
one week is regarded as a time-span during which recov-
ery would not affect diagnoses and long enough for most
persons not to remember previous replies. The first and
second interviews were separated by approximately a
week (mean 7.6 days, s.d. = 1.89). The two interview pro-
tocols, attached to each other, were sent to the researchers
(i.e. the authors) without names or personal ID:s of the
interviewed patients. Thus, patients were totally anonym-
ous to the researchers, and only known to the treatment
staff. This procedure was reviewed in the Research Ethics
Committee of Mid Sweden University without objections.
Thirty patients (27 men and 3 women, mean age 37 ys
[s.d. = 12.0]) agreed to participate. Nineteen were pa-
tients in three municipal residential treatment settings, 8
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bation office, and 3 were patients in opioid substitution
treatment at a psychiatric clinic. Participation was volun-
tary, and patients were assured that there would be no
negative consequences from the ADDIS assessment for
participation in their respective treatment programme.
The participants had 9–16 years of education (median =
12). Twelve were married, 4 divorced and 14 never mar-
ried. All reported having misused alcohol. I addition, 15
had misused (i.e. taken other than prescribed by a phys-
ician) tranquillizers or sleeping pills, and 10 had misused
analgesic. Sixteen had misused cannabis, 11 amphetamine,
8 cocaine, 8 inhalants, 7 hallucinogens and 6 heroin.
All were interviewed, for all substances used, in order
to examine SUDs criteria met in the three diagnostic
systems – ICD-10 (research version), DSM-IV and
DSM-5. When tabulated, fulfilled drug criteria and diag-
noses are reported according to drug categorisations
stipulated in the three diagnostic systems. In all these,
analgesics and heroin are collapsed to opioids, while tran-
quilizers and sleeping pills are categorised as “sedatives,
hypnotics and anxiolytics”. Inhalants are categorised as
“volatile solvents”, and amphetamines are categorised as
“other stimulants”, besides cocaine, while in DSM-5, am-
phetamines and cocaine are collapsed into “stimulants”.
In the statistical analyses two principal methods of test
agreement are Cohen’s Kappa (К) and Gamma (γ). К
estimates agreement when corrected for random agree-
ment, varying from 1 in case of perfect agreement, to 0
which is not more than random agreement. Negative
values exist when agreement is less than random.
Kappa can be interpreted as follows: <.00 = “poor”, 0.00 -
0.20 = “slight”, 0.21 - 0.40 = “fair”, 0.41 - 0.60 = “moderate”,
while 0.61-0.80 is “substantial” and >0.81 is “almost per-
fect” [18]. Gamma is a test of systematic correlation and is
here interpreted in the same way as К. Absolute agree-
ment is the percentage of protocols having identical out-
come on the particular criterion or diagnostic proposal
and is interpreted as follows: < 70% = “poor”, 70–79%
“moderate”, 80–89% = “satisfactory”, 90–99% = “excellent”,
100% = “perfect”. Internal consistency is tested with
Cronbach’s alpha (α), which is interpreted as “acceptable”
if α ≥ .50, as “satisfactory” when α ≥ .70, and “excellent”
when α ≥ .90 [19].
Results
Although analyses were conducted for the assessment of
both lifetime and current diagnoses with similar results,
only the current will be presented here in order to save
space.
Internal consistency on item and criteria level
The basis of ADDIS diagnostic assessment on SUDs are
47 items, of which two were 6-point Likert-scalequestions on quantity and frequency of alcohol use (but
not other drugs) and 45 are questions on symptoms
asked for all substance categories which can be answered
as follows: 0 =Not used, 1 = No, 2 = Yes, lifetime, 3 = Yes,
last year. Internal consistency using all relevant items is
extremely high for each of these categories (alcohol:
α = .95, all other drugs: α > .98). Since items are not
used to create scales, but organized according to cri-
teria of the diagnostic systems, ICD-10, DSM-IV and
DSM-5, the internal consistency on criteria level is
more relevant, and shown in Table 1 for the drug categor-
ies of each diagnostic system, respectively. The criteria of
the diagnostic categories harmful use in ICD-10, and
substance abuse in DSM-IV are added to the criteria of
substance dependence in the table.
All analyses show satisfactory or excellent internal
consistency. For instance, the mean internal consistency
across diagnostic systems range from an alpha of .86 for
alcohol (lowest) to .96 for sedatives, hypnotics and anxi-
olytics (highest). The overall mean alpha was .93. Thus,
there is strong evidence of inter-item reliability for all
types of drugs in all three diagnostic systems.
Test-retest correlations of number of fulfilled criteria
Systematic test-retest correlations on number of criteria
met for various drugs according to the diagnostic systems
are presented in Table 2. For ICD-10, agreement concern-
ing the dichotomous variable harmful use was investigated
with absolute as well as systematic agreement.
Systematic agreement of harmful use in ICD-10 range
from moderate to almost perfect (К:s = .46 - .93), with
the mean being borderline to almost perfect (.79).
Systematic correlations of dependence criteria in ICD-10
range from substantial to perfect (γ:s = .76 - 1.00), with
the mean being almost perfect (.92). Systematic correl-
ation concerning number of dependence criteria met in
DSM-IV were almost perfect or perfect (γ:s = .84 - 1.00),
and for substance abuse criteria, they range from ap-
proaching almost perfect to being perfect (γ:s = .80 - 1.00).
Systematic correlation on number of fulfilled DSM-5
criteria of substance use disorder range from substan-
tial to almost perfect (γ:s = .78 - .99). Subsequently,
systematic correlation on number of fulfilled criteria
are very high for all three diagnostic systems. The
mean systematic correlation range from .90 to .94 with
a summary mean of .92.
Test-retest agreement on diagnoses of SUDs
Based on number of various criteria met, test-retest reli-
ability of diagnostic proposals according to ICD-10 is
presented in Table 3 for each drug category.
Systematic agreement varied from fair (hallucinogens)
and moderate (volatile solvents, other stimulants) to sub-
stantial (alcohol, cocaine and opioids) and almost perfect
Table 1 Internal consistency (α) on criteria level of substance use disorders for the drug categories of ICD-10, DSM-IV
and DSM-5, respectively (n =30)
ICD-10 (7 criteria) a) DSM-IV (11 criteria) b) DSM-5 (11 criteria) Mean
Alcohol .87 .84 .87 .86
Sedatives, hypnotics, anxiolytics .97 .95 .96 .96
Cannabis/cannabinoids .97 .94 .95 .95
Cocaine c) .94 .93
.94 .93
Amphetamines/other stimulants c) .91 .93
Opioids .94 .95 .94 .94
Hallucinogens .98 .90 .90 .93
Volatile solvents .98 .89 .89 .92
Mean, all substances .95 .92 .92 .93
a) Includes 6 criteria on dependence and 1 on harmful use. b) Includes 7 criteria on dependence and 4 on abuse. c) Cocaine and amphetamines/other stimulants
are collapsed to stimulants in DSM-5.
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systematic agreement was substantial (Ƙ = .66). Absolute
agreements were all satisfactory or excellent (range:
.80 - .97; mean .91), and all systematic correlations were
almost perfect or indeed perfect (γ range: .92 - 1.00,
mean .97). Table 4 presents test-retest agreement con-
cerning DSM-IV diagnoses.
Here too, systematic agreement varied from fair to al-
most perfect. Differences, compared to ICD-10, were
lower agreement on alcohol (moderate) and cannabis
(substantial), while agreement on cocaine and amphet-
amines increased (almost perfect). Mean systematic
agreement approached substantial (Ƙ = .69). Absolute
agreements were all satisfactory or excellent (range: .87 - .97;
mean .93), and all systematic correlations were almost
perfect or indeed perfect (γ range: .89 - 1.00, mean .97).
Table 5 presents the agreement concerning DSM-5
diagnoses.Table 2 Systematic correlation (γ) between two assessments –







Alcohol .82 97 .84
Sedatives, hypnotics, anxiolytics .91 97 .93
Cannabinoids a) .97 97 .93
Cocaine b) .99 93 .79
Other stimulants c) .91 93 .83
Opioids d) .76 97 .92
Hallucinogens 1.00 97 .65
Volatile solvents 1.00 93 .46
Mean, all substances .92 96 .79
a) Cannabis in DSM-IV; b) Cocaine, amphetamines and other stimulants are collapse
amphetamine-like substances (not caffeine), while in DSM-5, stimulants also include
In addition, agreement concerning harmful use is tested with absolute agreement (As for the other two diagnostic systems, systematic
agreement varied from fair to almost perfect. In com-
parison to DSM-IV, alcohol improved from moderate to
substantial; cannabis was – as in ICD-10 – almost perfect;
and stimulants (cocaine as well as amphetamines/other
stimulants) were substantially in agreement. Opioids im-
proved to almost perfect. For sedatives/hypnotics/anxio-
lytics, hallucinogens and volatile solvents findings were
stable across diagnostic systems. As with ICD-10 and
DSM-IV, mean systematic agreement of DSM-5 diagnoses
was substantial (Ƙ = .65). Absolute agreement ranged from
substantial to excellent (87 to 93%, mean = 90), and all
systematic correlations were almost perfect or perfect
(γ range: .88 - 1.00, mean .95).
Summing up drug categories
Findings concerning inter-item consistency, and test-retest
consistency on criteria as well as diagnostic proposalstest, and retest after one week – as to number of



















d to stimulants in DSM-5; c) In ICD-10 this includes amphetamine and
cocaine; d) Includes opiates as well as synthetic opioids, e.g. analgesics.
%) as well as systematic agreement (К), (n = 30).
Table 3 Agreement between test and retest for ICD-10 diagnoses on substance use disorders (n = 30)
Retest\test No diagnose Harmful use Dependence Agreement measures
Alcohol No diagnose 3 0 1 К = .72 (p < 0.001)
Harmful use 0 0 1 γ = 1.00 (p = 0.041)
Dependence 0 0 25 Absolute agreement = .93
Sedatives, hypnotics, anxiolytics No diagnose 16 0 0 К = .93 (p < 0.001)
Harmful use 0 0 0 γ = 1.00 (p < 0.001)
Dependence 1 0 13 Absolute agreement = .97
Cannabinoids No diagnose 18 0 0 К = .87 (p < 0.001)
Harmful use 1 0 0 γ = 1.00 (p < 0.001)
Dependence 0 1 10 Absolute agreement = .93
Cocaine No diagnose 23 1 0 К = .68 (p < 0.001)
Harmful use 1 1 0 γ = .94 (p = 0.019)
Dependence 1 0 3 Absolute agreement = .90
Other stimulants No diagnose 21 1 0 К = .50 (p < 0.001)
Harmful use 1 0 2 γ = .92 (p < 0.001)
Dependence 1 1 3 Absolute agreement = .80
Opioids No diagnose 21 1 0 К = .77 (p < 0.001)
Harmful use 0 1 2 γ = 1.00 (p < 0.001)
Dependence 0 0 5 Absolute agreement = .90
Hallucinogens No diagnose 28 0 0 К = .31 (p = 0.021)
Harmful use 1 0 0 γ = 1.00 (n.s.)
Dependence 0 1 0 Absolute agreement = .93
Volatile solvents No diagnose 27 1 0 К = .47 (p = 0.001)
Harmful use 1 0 0 γ = .93 (n.s.)
Dependence 0 0 1 Absolute agreement = .93
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for each drug category.Alcohol
Internal consistency is satisfactory (α = .84 to .87). Sys-
tematic correlation between test and retest on number
of fulfilled criteria range from substantial to almost
perfect (γ = .78 to .84). Absolute agreement on diagnos-
tic level is satisfactory to excellent (87 to 93%), while
systematic agreement range from moderate to substan-
tial (К = .44 to .72), and systematic correlation is al-
most perfect or indeed perfect (γ = .88 to 1.00).Sedatives, hypnotics, anxiolytics
Internal consistency is excellent (α = .95 to .97). Sys-
tematic correlation on criteria level between test and
retest is almost perfect (γ = .84 to .93). On diagnostic
level absolute agreement between test and retest is sat-
isfactory to excellent (90 to 97%), while systematic
agreement is almost perfect (К = .81 to .93), and sys-
tematic correlation is almost perfect or perfect (γ = .98
to 1.00).Cannabis/cannabinoids
Internal consistency is excellent (α = .94 to .97). System-
atic correlation on criteria level between test and retest
is almost perfect (γ = .94 to .98). On diagnostic level
absolute agreement between test and retest is excellent
(90 to 93%), while systematic agreement is substantial or
almost perfect (К = .79 to .87), and systematic correlation
is almost perfect or perfect (γ = .97 to 1.00).
Cocaine, amphetamine and other stimulants
Internal consistency is excellent (α = .91 to .94). System-
atic correlation on criteria level between test and retest
is almost perfect or perfect (γ = .90 to 1.00). On diag-
nostic level absolute agreement between test and re-
test is satisfactory to excellent (80 to 97%), while
systematic agreement range from moderate to almost
perfect (К = .50 to .89), and systematic correlation is
almost perfect or perfect (γ = .92 to 1.00).
Opioids
Internal consistency is excellent (α = .94 to .95). Systematic
correlation on criteria level between test and retest is sub-
stantial to almost perfect (γ = .76 to .97). On diagnostic
Table 4 Agreement between test and retest for DSM-IV diagnoses on substance use disorders (n = 30)
Retest\test No diagnose Abuse Dependence Agreement measures
Alcohol No diagnose 2 0 2 К = .44 (p = 0.002)
Abuse 0 0 1 γ = .89 (n.s.)
Dependence 0 1 24 Absolute agreement = .87
Sedatives, hypnotics, anxiolytics No diagnose 16 0 0 К = .93 (p < 0.001)
Abuse 0 0 0 γ = 1.00 (p < 0.001)
Dependence 1 0 13 Absolute agreement = .97
Cannabis No diagnose 17 0 1 К = .79 (p < 0.001)
Abuse 1 0 0 γ = .98 (p < 0.001)
Dependence 1 0 10 Absolute agreement = .90
Cocaine No diagnose 24 1 0 К = .89 (p < 0.001)
Abuse 0 1 0 γ = 1.00 (p = 0.003)
Dependence 0 0 4 Absolute agreement = .97
Amphetamine (or No diagnose 23 0 0 К = .82 (p < 0.001)
amphetamine-like) Abuse 0 0 1 γ = .99 (p < 0.001)
Dependence 0 1 5 Absolute agreement = .93
Opioids No diagnose 20 1 2 К = .77 (p < 0.001)
Abuse 0 1 0 γ = .97 (p < 0.001)
Dependence 0 0 6 Absolute agreement = .90
Hallucinogens No diagnose 28 0 0 К = .31 (p = 0.021)
Abuse 1 0 0 γ = 1.00 (n.s.)
Dependence 0 1 0 Absolute agreement = .93
Volatile solvents No diagnose 27 1 0 К = .47 (p = 0.001)
Abuse 1 0 0 γ = .93 (n.s.)
Dependence 0 0 1 Absolute agreement = .93
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lent (90 to 93%), while systematic agreement is substantial
or almost perfect (К = .77 to .85), and systematic correl-
ation is almost perfect or perfect (γ = .97 to 1.00).Hallucinogens
Internal consistency is excellent (α = .90 to .98). Systematic
correlation on criteria level between test and retest is al-
most perfect or indeed perfect (γ = .88 to 1.00). On diag-
nostic level absolute agreement between test and retest is
excellent (90 to 93%), while systematic agreement is only
fair (К = .21 to .31), and the systematic correlation is al-
most perfect or perfect (γ = .93 to 1.00).Volatile solvents
Internal consistency is satisfactory to excellent (α = .89
to .98). Systematic correlation on criteria level between
test and retest is almost perfect to perfect (γ = .93 to
1.00). On diagnostic level absolute agreement between
test and retest is excellent (all 93%), while systematic
agreement is moderate (all К = .47), and systematic cor-
relation is almost perfect (all γ = .93).Reliability of scales concerning stress, anxiety and
depression
The scales for screening stressful life events, anxiety and
depression were analysed for inter-item as well as for
test-retest consistency (n = 27). Internal consistency was
satisfactory for stress (α = .72), and excellent for anxiety
and depression (α = .90 and .96, respectively). Test-retest
showed almost perfect systematic correlation for all
scales (stressful life events: γ = .85; anxiety: γ = .96, and
depression: γ = .92).
Discussion
The study has some obvious limitations. It was con-
ducted without external funding. A convenience sample
was used. The cooperating treatment facilities conducted
interviews on their own budgets. The sample is therefore
smaller than would have been preferred, but about the
same as in similar studies e.g. [20-22].
Due to the variety of patients enrolled, and despite the
relatively small sample, it was possible to include all
types of drugs that might be assessed using ADDIS with
more than five cases for each condition, a cut-off used in
e.g. Zanarini et al. [16]. These drugs were, as expected,
Table 5 Agreement between test and retest for DSM-5 diagnoses on substance use disorders (n = 30)
Retest\test No diagnose Mild Moderate Severe Agreement measures
Alcohol No diagnose 2 0 0 2 К = .71 (p < 0.001)
Mild 0 0 1 0 γ = .88 (p = 0.001)
Moderate 0 0 4 1 Absolute
Severe 0 0 0 20 agreement = .87
Sedatives, hypnotics, anxiolytics No diagnose 16 0 0 0 К = .81 (p < 0.001)
Mild 0 0 0 0 γ = .98 (p < 0.001)
Moderate 0 0 0 1 Absolute
Severe 1 0 1 11 agreement = .90
Cannabis No diagnose 15 1 0 0 К = .83 (p < 0.001)
Mild 1 2 0 0 γ = .97 (p < 0.001)
Moderate 1 0 0 0 Absolute
Severe 0 0 0 10 agreement = .90
Stimulants No diagnose 22 0 0 0 К = .67 (p < 0.001)
Mild 1 0 0 1 γ = .98 (p < 0.001)
Moderate 0 0 0 0 Absolute
Severe 0 0 2 4 agreement = .87
Opioids No diagnose 21 1 0 0 К = .85 (p < 0.001)
Mild 0 2 0 0 γ = 1.00 (p < 0.001)
Moderate 0 0 0 1 Absolute
Severe 0 0 0 5 agreement = .93
Hallucinogens No diagnose 27 1 0 0 К = .21 (n.s.)
Mild 1 0 0 0 γ = .93 (n.s.)
Moderate 0 0 0 0 Absolute
Severe 0 1 0 0 agreement = .90
Volatile solvents No diagnose 27 1 0 0 К = .47 (p = 0.001)
Mild 1 0 0 0 γ = .93 (n.s.)
Moderate 0 0 0 0 Absolute
Severe 0 0 0 1 agreement = .93
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skewness in number of cases vs. non-cases. Systematic
agreement (Cohen’s Kappa) and systematic correlation
(Gamma) handles such skewness to some degree. While
Kappa tends to be lower than Gamma on skewed cat-
egories, Gamma tends to be more conservative in testing
statistical significance (p-values). We therefore present
both of these.
The relatively lower Kappa values for hallucinogens,
volatile solvents and alcohol may be related to skewness
of these variables – with relatively few who used halluci-
nogens and volatile solvents and with almost everyone
having some problem concerning alcohol. The problem
was not however indicated by absolute agreement or sys-
tematic correlation.
Taking all drug categories together, ADDIS has an
excellent overall mean internal consistency of .93. Test-
retest correlation on number of fulfilled criteria is veryhigh for all three diagnostic systems. Their mean system-
atic correlations on criteria level for various drugs and
diagnostic systems are almost perfect (.92 - .94). At the
level of diagnostic proposals across all three diagnos-
tic systems, mean systematic agreement is substantial
(Ƙ = .65 - .69), while mean absolute agreement is excellent
(90 - 93%), and mean systematic correlation is almost per-
fect (γ = .95-.97).
Both internal and global consistencies are equivalent
to or better than previously found concerning: SUDDS
for DSM-III-R and DSM-IV [11,13]; different versions of
SCID for DSM-IV [16,20,23-25] different versions of
MINI for DSM-III-R and DSM-IV [17,22]; and the
Composite International Diagnostic Interview (CIDI)
for ICD-10 and DSM-III-R [26].
In addition, screening tests on stressful life events,
anxiety and depression showed satisfactory to excellent
internal consistency (α = .72, .90 and .96 respectively),
Gerdner and Wickström Substance Abuse Treatment, Prevention, and Policy  (2015) 10:14 Page 8 of 8and almost perfect global consistency for all scales
(γ = .84 - .96).
Despite the small sample, the reliability findings are
sufficiently striking so as to indicate that the ADDIS
consistently provides substance specific diagnostic docu-
mentation. ADDIS is the only currently used instrument
in Swedish, which is capable of providing substance
specific diagnostic information in a relatively brief inter-
view to be practical in routine clinical practice. Further
research with a larger and more diverse sample is indi-
cated to extend the findings of the current study.
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